Deals
Baxalta Said in Talks to Buy Ariad to Boost Cancer Offerings
- Ariad has drugs in development for leukemia, lung cancers
- Discussions continue and may not result in a deal being done
This article is for subscribers only.
Baxalta Inc., the drugmaker fending off a $30 billion takeover offer from Shire Plc, is in talks to acquire Ariad Pharmaceuticals Inc. to boost its oncology business, people with knowledge of the matter said.
Discussions with the developer of leukemia and lung-cancer treatments continue and there is no certainty a deal will be reached, said the people, who asked not to be identified because the information is private. Baxalta could also choose to pursue other targets.